Important Claim Against Fosomax Dismissed

Releasing a statement on Tuesday, Merck & Co. revealed that a U.S. district court dismissed claims against the company in a second  “bellwether” or “key” regarding the drug Fosomax.   As of Sept. 30, the company has been fighting 953 lawsuits  which   allege that  their   osteoporosis drug Fosamax causes a painful ailment called osteonecrosis of the jaw.     The disorder culminates in a loss of blood  to the bones, permanently damaging them.

U.S. District Court Judge John F. Keenan granted Merck summary judgment in the case stating that the  plaintiff’s physician was unqualified to render an opinion in the matter.  He also indicated that the evidence presented was insufficient to show a causal link between  Fosomax and osteonecrosis of the jaw.

Fosomax has been  approved to treat the thinning of bone tissue and loss of bone density.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.